id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2013-D-0575-0036,FDA,FDA-2013-D-0575,Agency Information Collection Activities; Proposed Collection; Comment Request; Guidance for Industry on Expedited Programs for Serious Conditions—Drugs and Biologics,Notice,60 Day Proposed Information Collection,2017-11-08T05:00:00Z,2017,11,2017-11-08T05:00:00Z,2018-01-09T04:59:59Z,2017-11-08T15:41:39Z,2017-24296,0,0,0900006482c5836f
FDA-2013-D-0575-0035,FDA,FDA-2013-D-0575,"Agency Information Collection Activities; Announcement of Office of
Management and Budget Approvals",Notice,Notice of Approval,2017-07-03T04:00:00Z,2017,7,2017-07-03T04:00:00Z,,2017-07-03T15:56:36Z,2017-13890,0,0,09000064827deed9
FDA-2013-D-0575-0034,FDA,FDA-2013-D-0575,"Agency Information Collection Activities; Submission for Office of
Management and Budget Review; Comment Request; Guidance for
Industry on Expedited Programs for Serious Conditions—Drugs and
Biologics",Notice,30 Day Proposed Information Collection,2017-03-15T04:00:00Z,2017,3,2017-03-15T04:00:00Z,2017-04-15T03:59:59Z,2017-03-15T15:14:46Z,2017-05104,0,0,0900006482508722